查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1250770

到 2028 年的多汗症治療市場預測 - 按治療類型、疾病類型、最終用戶和地區進行的全球分析

Hyperhidrosis Treatment Market Forecasts to 2028 - Global Analysis By Treatment Type, Disease Type, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2022 年全球多汗症治療市場規模將達到 6161 億美元，預計到 2028 年將達到 9298 億美元，預測期內復合年增長率為 7.1%。

不一定由熱或勞累引起的過度出汗被稱為多汗症。您可能會大量出汗，滲出衣服或從手上滴落。出汗過多會毀了你的一天，並導致社交焦慮和尷尬。多汗症的治療通常從止汗劑開始有效。繼發性多汗症患病率上升、市場進入者增加研發支出是推動多汗症治療市場增長的關鍵因素。

發表在《Scientific Reports》雜誌上的一項 2021 年研究報告稱，與條件相同但接受不同治療的人相比，在四個不同部位接受肉毒桿菌毒素注射的人報告的焦慮跡像要少得多。

市場動態

促進者

增加研發活動和戰略夥伴關係

與該領域相關的最新研究和開發計劃在世界範圍內越來越受歡迎。例如，Brickell Biotech Inc. 報告了關鍵的 3 期 Cardigan I 和 Cardigan II 試驗的積極結果，該試驗評估了 15% 的軟□溴銨凝膠作為原發性腋窩多汗症患者每日一次的局部製劑。我們發布了頂級結果並推動市場生長。患有多汗症的患者尋求提供合理和有益緩解的家庭療法，尤其是兒童。然而，與各種行業參與者和組織的戰略夥伴關係和合作正在推動市場增長。

阻礙因素

成本高

治療程序的高成本阻礙了市場的擴大。由於缺乏可接受的支付計劃或組織的特殊考慮，患者往往無法採用這些高端治療，從而對健康產生重大影響。因此，這是必須解決的固有限制。此外，治療可能會增加代償性出汗，阻礙市場增長。

機會

多汗症患者增加

這種疾病在美國的患病率估計約為 3%。多汗症會導致情緒、心理、社交和職業困難。因此，預計多汗症患病率的增加將增加對治療的需求，從而導致市場增長。Onabotulinum 毒素 A 可用於治療較小身體區域（例如腋窩、手、腳、頭和臉）的過度出汗。保妥適已被證明可顯著減少 82-87% 的出汗。它是市場領先的，因為它在治療後 2-4 天內顯示結果，並在 2 週內完全生效。

威脅

副作用

保妥適有很多副作用。肌肉無力、眼部問題和呼吸困難等副作用會嚴重困擾患者並阻礙市場擴張。此外，潛在的副作用包括口乾、視力模糊和膀胱問題。背部、腹部、大腿和腿部出汗過多是最令人不快的副作用，阻礙了市場。

COVID-19 的影響

預計 COVID-19 大流行將減緩全球多汗症藥物市場的增長。然而，在大流行期間，儘管有避免社會孤立的警告，但許多人還是採取了自我藥療和其他替代方法來治療他們的疾病。在大流行期間，多汗症患者患抑鬱症的風險異常高，尤其是女性患者，其中一些患者報告難以獲得治療。

預計在預測期內手術治療部分將是最大的

由於專業的汗液測試以查看出汗量是否在正常範圍內，估計外科治療領域將出現有利可圖的增長。醫務人員使用非手術方法治療多汗症，包括止汗劑、肌肉鬆弛劑注射和藥物治療。然而，這些治療只能短期緩解症狀。使用小型內窺鏡和諧波刀片切除過度活躍的神經節段。這種巧妙的刀片以高頻振動並產生很少的熱量，從而保護鄰近的神經。手術可以長期緩解過度出汗。手術引起的多汗症需要3mm以下的切口，神經的可視性提高，手術的精度提高，手術的痛苦減輕，恢復時間縮短，問題也少，因此侵入性小。我們正在促進市場的發展，因為有不是這樣的東西

預計原發性局灶性多汗症部分將在預測期內見證最高的複合年增長率。

預計原發性局灶性多汗症部分將在預測期內呈現最快的複合年增長率。這是因為處方止汗劑可能會開出含有氯化鋁的止汗劑。神經阻斷藥、處方藥膏和濕巾用於有效治療腋窩、手掌和腳底。其他受影響的區域包括面部、頭皮、腹股溝和乳腺下腺。原發性多汗症是由使小汗腺過度勞累的錯誤神經信號引起的。症狀通常出現在手掌、腳底、腋窩，有時還會出現在面部。

市場佔有率最高的地區

北美將在 2021 年佔據全球多汗症治療市場份額的大部分，預計在預測期內佔據最大的市場份額，並預計在預測期內保持其主導地位。這是由於多汗症治療技術的進步、患病率的上升以及關鍵而強大的醫療基礎設施的可用性。預計這一數字將顯著增長。

複合年增長率最高的地區：

由於以下原因，預計歐洲在預測期內的複合年增長率最高。該地區原發性和繼發性多汗症的高患病率可能會導致廣泛的治療。由於患病率高，一些治療藥物在該地區使用較多，例如商業六水合氯化鋁 20.0%。這樣的優勢會增加產品的消費需求，帶來市場的擴大。原發性多汗症、癌症、心血管疾病、繼發性多汗症的增加、技術的改進以及該地區重要市場進入者的存在正在促進增長。

市場的重要參與者

多汗症治療市場的主要參與者包括 Brickell Biotech Inc、Eli Lilly and Company、AbbVie Inc、1315 Capital、Merz Pharma、Dermadry Laboratories Inc、Dermata Therapeutics Inc、Advin Health Care、Dermavant Sciences Inc、TheraVida、NovaMedica、Eirion Therapeutics, Inc 、Roivant Sciences Ltd、GSK Plc、GlaxoSmithKline PLC 和 Sesderma。

重大發展

2023 年 1 月，AbbVie 和 Anima Biotech 宣布合作發現和開髮用於癌症和免疫靶標的 mRNA 生物調節劑。Anima 將使用其 mRNA 閃電平台發現針對聯合品牌目標的新型 mRNA 生物調節劑，並將向 AbbVie 提供許可、進一步開發和商業化該項目的獨家權利。

2022年12月，AbbVie啟動與HotSpot Therapeutics的戰略合作，進一步拓展免疫學管線，與HotSpot合作為患有嚴重自身免疫性疾病的患者提供全新的靶向類調節劑成為可能。

2022 年 12 月，Dermavant 推出了第一個 VTAMA(R) (Tapinalof) Cream 1% 商業廣告，作為針對成年尋常型銀屑病患者的全國性多媒體宣傳活動的一部分。許多人等待 VTAMA 乳膏等不同的尋常型銀屑病藥物已等待很長時間。

2022 年 6 月，Dermata 宣布最後一名患者參加了每週一次的 DMT310 治療中度至重度酒渣鼻的 2 期試驗，DMT310 適用於治療多種炎症性皮膚病，包括我目前正在研究的酒渣鼻、痤瘡和牛皮癬。

本報告內容

  • 區域和國家細分市場份額評估
  • 對新進入者的戰略建議
  • 涵蓋 2020、2021、2022、2025 和 2028 年的市場數據
  • 市場驅動因素（市場趨勢、制約因素、機會、威脅、挑戰、投資機會/建議等）
  • 基於市場估計的關鍵業務領域的戰略建議
  • 競爭格局和趨勢
  • 公司概況，包括詳細戰略、財務狀況和近期發展
  • 供應鏈趨勢反映了最新的技術進步。

提供免費定制

購買此報告的客戶將免費獲得以下定制之一。

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 個）
    • 主要參與者的SWOT分析（最多3人）
  • 區域部分
    • 應客戶要求提供主要國家的市場預估、預測和CAGR（注：通過可行性檢查）
  • 競爭標桿
    • 根據產品組合、地域分佈和戰略聯盟對主要參與者進行基準測試

目錄

第一章內容提要

第二章前言

  • 概述
  • 利益相關者
  • 調查範圍
  • 調查方法
    • 數據挖掘
    • 數據分析
    • 數據驗證
    • 研究方法
  • 研究來源
    • 主要研究來源
    • 二手研究資源
    • 假設

第三章市場趨勢分析

  • 促進者
  • 抑製劑
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5 全球多汗症治療市場，按治療類型

  • 手術治療
  • 局部治療
  • 肉毒素A
  • 激光療法
  • 離子電滲療法
  • 其他治療類型

6 全球多汗症治療市場，按疾病類型

  • 原發性局灶性多汗症
  • 繼發性全身性多汗症

7. 全球多汗症治療市場，按最終用戶分類

  • 醫院
  • 家庭護理
  • 專科中心
  • 其他最終用戶

8.按地區分列的全球多汗症治療市場

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 意大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 新西蘭
    • 韓國
    • 亞太其他地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中東和非洲
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 卡塔爾
    • 南非
    • 其他中東

第九章主要進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第十章公司簡介

  • Brickell Biotech Inc.
  • Eli Lilly and Company
  • AbbVie Inc
  • 1315 Capital
  • Merz Pharma
  • Dermadry Laboratories Inc.
  • Dermata Therapeutics Inc.
  • Advin Health Care
  • Dermavant Sciences Inc.
  • TheraVida
  • NovaMedica
  • Eirion Therapeutics, Inc
  • Roivant Sciences Ltd
  • GSK Plc
  • GlaxoSmithKline PLC
  • Sesderma
Product Code: SMRC22647

According to Stratistics MRC, the Global Hyperhidrosis Treatment Market is accounted for $616.1 billion in 2022 and is expected to reach $929.8 billion by 2028 growing at a CAGR of 7.1% during the forecast period. Excessive sweating that is not necessarily caused by heat or exertion is known as hyperhidrosis. Sweating so intensely that it soaks through your clothes or drips off your hands is possible. Sweating excessively can ruin your day and cause social anxiety and shame. Treatment for hyperhidrosis is usually effective it usually starts with antiperspirants. The rise in the prevalence of secondary hyperhidrosis disorders, as well as the increase in research and development expenditure by market participants, are significant drivers driving the growth of the hyperhidrosis treatment market.

According to a study published in the journal Scientific Reports in 2021, people who received Botox injections at four different sites reported significantly fewer signs of anxiety than those who received different treatments for the same conditions.

Market Dynamics:

Driver:

Increasing R&D activity and strategic partnerships

The most recent R&D initiatives related to the sector are gaining popularity around the world. Brickell Biotech Inc., for example, announced favourable topline results from the Phase 3 pivotal Cardigan I and Cardigan II studies that assessed sofpironium bromide gel, 15% as a once-daily topical formulation in patients with primary axillary hyperhidrosis this increases market growth. Patients suffering from hyperhidrosis want home treatments that provide reasonable and beneficial relief, particularly for children. However strategic partnerships and collaborations between various industry companies and organisations are assisting in market growth.

Restraint:

High cost

The high cost of treatment procedures stifles market expansion. Patients frequently fail to adopt these high-end treatment alternatives due to a lack of acceptable payment plans and special considerations by organisations, which have a significant impact on their health. As a result, this is an essential constraint that must be addressed. Moreover, the treatment may lead to the increased compensatory sweating which hampers the market growth.

Opportunity:

Rise in hyperhidrosis case

The prevalence of this illness in the United States is estimated to be around 3%. Hyperhidrosis can cause emotional, psychological, social, and vocational difficulties. As a result, the increased prevalence of hyperhidrosis is predicted to enhance demand for therapy and consequently market growth. Onabotulinumtoxin A can be used to treat excessive sweating in the armpits, hands, feet, head, and face, as well as other relatively tiny body locations. Botox has been demonstrated to significantly reduce perspiration by 82-87%. The benefits appear 2 to 4 days after treatment, with the full results evident within two weeks thereby propelling the market.

Threat:

Side effects

Botox is connected with a number of adverse effects. Consequences such as muscle weakness, eye problems, and breathing difficulties are significantly hurting patients and stifling market expansion. Furthermore, potential adverse effects include dry mouth, impaired vision, and bladder issues. Excessive sweating on the back, belly, thighs, or lower legs is the most unpleasant side effect which hampers the market.

Covid-19 Impact

The COVID-19 pandemic is expected to slow the growth of the global market for hyperhidrosis remedies. During the pandemic, however, many individuals treated their ailments via self-medication or other alternative ways, despite warnings to keep social isolation. During the pandemic, individuals with hyperhidrosis had a disproportionately greater risk of depression, particularly among female patients, and some of these patients reported difficulty accessing therapy.

The Surgical treatments segment is expected to be the largest during the forecast period

The Surgical treatments segment is estimated to have a lucrative growth, due to its specialist sweat test that can assist establish if the amount of perspiration your body produces is within normal limits. Medical professionals addressed hyperhidrosis with nonsurgical approaches such as antiperspirants, muscle relaxing injections, and medicines. These treatments only provide short relief from symptoms. Using a small endoscope and a harmonic blade, remove a segment of the hyperactive nerve. This clever blade vibrates at high frequencies and produces little heat, protecting adjacent nerves. Surgery provides long-term relief from excessive sweating. Surgical hyperhidrosis less invasive incisions of less than three millimetres, improved nerve vision for more precise surgery, reduced surgical pain, a shorter recovery period, and no problems there by encouraging in the market growth.

The Primary focal hyperhidrosis segment is expected to have the highest CAGR during the forecast period

The Primary focal hyperhidrosis segment is anticipated to witness the fastest CAGR growth during the forecast period, due to antiperspirant on prescription doctor may prescribe an antiperspirant containing aluminium chloride. Medication that blocks nerves, prescribed creams and wipes are used to effectively treat the axillae, palms, and soles are commonly affected by primary focal hyperhidrosis. Other locations that may be affected include the face, scalp, inguinal, and inframammary areas. Primary hyperhidrosis is produced by incorrect nerve signals, which cause eccrine sweat glands to overwork. It typically affects the palms, soles, underarms, and occasionally the face.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to a majority of the worldwide hyperhidrosis treatment market share in 2021 and is predicted to continue dominant during the forecast period. This is due to technological advances in hyperhidrosis treatment, a elevated incidence of disease, and the availability of critical and robust medical infrastructure in the region to see significant growth as the patient population grows, healthcare infrastructure develops, and investment initiatives in the region expand.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period, owing to The high frequency of primary and secondary hyperhidrosis in the region will increase treatment uptake. Because of the high prevalence, several therapies, such as over-the-counter aluminium chloride hexahydrate 20.0% in the region, have seen greater use. Such predominance will enhance demand for product consumption, resulting in market expansion. The increasing burden of primary hyperhidrosis, cancer, and cardiovascular problems, rises in secondary hyperhidrosis, technological improvements, and the existence of important market participants in the region are all contributing to the growth.

Key Players in the market

Some of the key players profiled in the Hyperhidrosis Treatment Market include Brickell Biotech Inc, Eli Lilly and Company, AbbVie Inc, 1315 Capital, Merz Pharma, Dermadry Laboratories Inc, Dermata Therapeutics Inc., Advin Health Care, Dermavant Sciences Inc, TheraVida, NovaMedica, Eirion Therapeutics, Inc, Roivant Sciences Ltd, GSK Plc, GlaxoSmithKline PLC and Sesderma

Key Developments:

In Jan 2023, AbbVie and Anima Biotech Announce Collaboration for the Discovery and Development of mRNA Biology Modulators against Oncology and Immunology Targets, Anima will use its mRNA Lightning platform to discover novel mRNA biology modulators against the collaboration targets providing AbbVie exclusive rights to license and further develop and commercialize the programs.

In Dec 2022, AbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline this collaboration with HotSpot has the potential to deliver an entirely new target class of modulators to patients with serious autoimmune diseases

In Dec 2022, Dermavant Launched First Commercial for VTAMA® (tapinarof) cream, 1% as Part of a National, Multimedia Campaign for Adults with Plaque Psoriasis many have been waiting a long time for a different plaque psoriasis treatment like VTAMA cream.

In June 2022, Dermata Announces Final Patient Enrolled in a Phase 2 Trial of DMT310 for the Once-Weekly Treatment of Moderate-to-Severe Rosacea, DMT310 is currently being investigated to treat multiple inflammatory skin conditions, including rosacea, acne, and psoriasis.

Treatment Types Covered:

  • Surgical Treatments
  • Topical Treatments
  • Botulin Toxin A
  • Laser Treatments
  • Iontophoresis
  • Other Treatment Types

Disease Types Covered:

  • Primary Focal Hyperhidrosis
  • Secondary Generalized Hyperhidrosis

End Users Covered:

  • Hospitals
  • Homecare
  • Speciality Centres
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Hyperhidrosis Treatment Market, By Treatment Type

  • 5.1 Introduction
  • 5.2 Surgical Treatments
  • 5.3 Topical Treatments
  • 5.4 Botulin Toxin A
  • 5.5 Laser Treatments
  • 5.6 Iontophoresis
  • 5.7 Other Treatment Types

6 Global Hyperhidrosis Treatment Market, By Disease Type

  • 6.1 Introduction
  • 6.2 Primary Focal Hyperhidrosis
  • 6.3 Secondary Generalized Hyperhidrosis

7 Global Hyperhidrosis Treatment Market, By End User

  • 7.1 Introduction
  • 7.2 Hospitals
  • 7.3 Homecare
  • 7.4 Speciality Centres
  • 7.5 Other End Users

8 Global Hyperhidrosis Treatment Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Brickell Biotech Inc.
  • 10.2 Eli Lilly and Company
  • 10.3 AbbVie Inc
  • 10.4 1315 Capital
  • 10.5 Merz Pharma
  • 10.6 Dermadry Laboratories Inc.
  • 10.7 Dermata Therapeutics Inc.
  • 10.8 Advin Health Care
  • 10.9 Dermavant Sciences Inc.
  • 10.10 TheraVida
  • 10.11 NovaMedica
  • 10.12 Eirion Therapeutics, Inc
  • 10.13 Roivant Sciences Ltd
  • 10.14 GSK Plc
  • 10.15 GlaxoSmithKline PLC
  • 10.16 Sesderma

List of Tables

  • Table 1 Global Hyperhidrosis Treatment Market Outlook, By Region (2020-2028) ($MN)
  • Table 2 Global Hyperhidrosis Treatment Market Outlook, By Treatment Type (2020-2028) ($MN)
  • Table 3 Global Hyperhidrosis Treatment Market Outlook, By Surgical Treatments (2020-2028) ($MN)
  • Table 4 Global Hyperhidrosis Treatment Market Outlook, By Topical Treatments (2020-2028) ($MN)
  • Table 5 Global Hyperhidrosis Treatment Market Outlook, By Botulin Toxin A (2020-2028) ($MN)
  • Table 6 Global Hyperhidrosis Treatment Market Outlook, By Laser Treatments (2020-2028) ($MN)
  • Table 7 Global Hyperhidrosis Treatment Market Outlook, By Iontophoresis (2020-2028) ($MN)
  • Table 8 Global Hyperhidrosis Treatment Market Outlook, By Other Treatment Types (2020-2028) ($MN)
  • Table 9 Global Hyperhidrosis Treatment Market Outlook, By Disease Type (2020-2028) ($MN)
  • Table 10 Global Hyperhidrosis Treatment Market Outlook, By Primary Focal Hyperhidrosis (2020-2028) ($MN)
  • Table 11 Global Hyperhidrosis Treatment Market Outlook, By Secondary Generalized Hyperhidrosis (2020-2028) ($MN)
  • Table 12 Global Hyperhidrosis Treatment Market Outlook, By End User (2020-2028) ($MN)
  • Table 13 Global Hyperhidrosis Treatment Market Outlook, By Hospitals (2020-2028) ($MN)
  • Table 14 Global Hyperhidrosis Treatment Market Outlook, By Homecare (2020-2028) ($MN)
  • Table 15 Global Hyperhidrosis Treatment Market Outlook, By Speciality Centres (2020-2028) ($MN)
  • Table 16 Global Hyperhidrosis Treatment Market Outlook, By Other End Users (2020-2028) ($MN)
  • Table 17 North America Hyperhidrosis Treatment Market Outlook, By Country (2020-2028) ($MN)
  • Table 18 North America Hyperhidrosis Treatment Market Outlook, By Treatment Type (2020-2028) ($MN)
  • Table 19 North America Hyperhidrosis Treatment Market Outlook, By Surgical Treatments (2020-2028) ($MN)
  • Table 20 North America Hyperhidrosis Treatment Market Outlook, By Topical Treatments (2020-2028) ($MN)
  • Table 21 North America Hyperhidrosis Treatment Market Outlook, By Botulin Toxin A (2020-2028) ($MN)
  • Table 22 North America Hyperhidrosis Treatment Market Outlook, By Laser Treatments (2020-2028) ($MN)
  • Table 23 North America Hyperhidrosis Treatment Market Outlook, By Iontophoresis (2020-2028) ($MN)
  • Table 24 North America Hyperhidrosis Treatment Market Outlook, By Other Treatment Types (2020-2028) ($MN)
  • Table 25 North America Hyperhidrosis Treatment Market Outlook, By Disease Type (2020-2028) ($MN)
  • Table 26 North America Hyperhidrosis Treatment Market Outlook, By Primary Focal Hyperhidrosis (2020-2028) ($MN)
  • Table 27 North America Hyperhidrosis Treatment Market Outlook, By Secondary Generalized Hyperhidrosis (2020-2028) ($MN)
  • Table 28 North America Hyperhidrosis Treatment Market Outlook, By End User (2020-2028) ($MN)
  • Table 29 North America Hyperhidrosis Treatment Market Outlook, By Hospitals (2020-2028) ($MN)
  • Table 30 North America Hyperhidrosis Treatment Market Outlook, By Homecare (2020-2028) ($MN)
  • Table 31 North America Hyperhidrosis Treatment Market Outlook, By Speciality Centres (2020-2028) ($MN)
  • Table 32 North America Hyperhidrosis Treatment Market Outlook, By Other End Users (2020-2028) ($MN)
  • Table 33 Europe Hyperhidrosis Treatment Market Outlook, By Country (2020-2028) ($MN)
  • Table 34 Europe Hyperhidrosis Treatment Market Outlook, By Treatment Type (2020-2028) ($MN)
  • Table 35 Europe Hyperhidrosis Treatment Market Outlook, By Surgical Treatments (2020-2028) ($MN)
  • Table 36 Europe Hyperhidrosis Treatment Market Outlook, By Topical Treatments (2020-2028) ($MN)
  • Table 37 Europe Hyperhidrosis Treatment Market Outlook, By Botulin Toxin A (2020-2028) ($MN)
  • Table 38 Europe Hyperhidrosis Treatment Market Outlook, By Laser Treatments (2020-2028) ($MN)
  • Table 39 Europe Hyperhidrosis Treatment Market Outlook, By Iontophoresis (2020-2028) ($MN)
  • Table 40 Europe Hyperhidrosis Treatment Market Outlook, By Other Treatment Types (2020-2028) ($MN)
  • Table 41 Europe Hyperhidrosis Treatment Market Outlook, By Disease Type (2020-2028) ($MN)
  • Table 42 Europe Hyperhidrosis Treatment Market Outlook, By Primary Focal Hyperhidrosis (2020-2028) ($MN)
  • Table 43 Europe Hyperhidrosis Treatment Market Outlook, By Secondary Generalized Hyperhidrosis (2020-2028) ($MN)
  • Table 44 Europe Hyperhidrosis Treatment Market Outlook, By End User (2020-2028) ($MN)
  • Table 45 Europe Hyperhidrosis Treatment Market Outlook, By Hospitals (2020-2028) ($MN)
  • Table 46 Europe Hyperhidrosis Treatment Market Outlook, By Homecare (2020-2028) ($MN)
  • Table 47 Europe Hyperhidrosis Treatment Market Outlook, By Speciality Centres (2020-2028) ($MN)
  • Table 48 Europe Hyperhidrosis Treatment Market Outlook, By Other End Users (2020-2028) ($MN)
  • Table 49 Asia Pacific Hyperhidrosis Treatment Market Outlook, By Country (2020-2028) ($MN)
  • Table 50 Asia Pacific Hyperhidrosis Treatment Market Outlook, By Treatment Type (2020-2028) ($MN)
  • Table 51 Asia Pacific Hyperhidrosis Treatment Market Outlook, By Surgical Treatments (2020-2028) ($MN)
  • Table 52 Asia Pacific Hyperhidrosis Treatment Market Outlook, By Topical Treatments (2020-2028) ($MN)
  • Table 53 Asia Pacific Hyperhidrosis Treatment Market Outlook, By Botulin Toxin A (2020-2028) ($MN)
  • Table 54 Asia Pacific Hyperhidrosis Treatment Market Outlook, By Laser Treatments (2020-2028) ($MN)
  • Table 55 Asia Pacific Hyperhidrosis Treatment Market Outlook, By Iontophoresis (2020-2028) ($MN)
  • Table 56 Asia Pacific Hyperhidrosis Treatment Market Outlook, By Other Treatment Types (2020-2028) ($MN)
  • Table 57 Asia Pacific Hyperhidrosis Treatment Market Outlook, By Disease Type (2020-2028) ($MN)
  • Table 58 Asia Pacific Hyperhidrosis Treatment Market Outlook, By Primary Focal Hyperhidrosis (2020-2028) ($MN)
  • Table 59 Asia Pacific Hyperhidrosis Treatment Market Outlook, By Secondary Generalized Hyperhidrosis (2020-2028) ($MN)
  • Table 60 Asia Pacific Hyperhidrosis Treatment Market Outlook, By End User (2020-2028) ($MN)
  • Table 61 Asia Pacific Hyperhidrosis Treatment Market Outlook, By Hospitals (2020-2028) ($MN)
  • Table 62 Asia Pacific Hyperhidrosis Treatment Market Outlook, By Homecare (2020-2028) ($MN)
  • Table 63 Asia Pacific Hyperhidrosis Treatment Market Outlook, By Speciality Centres (2020-2028) ($MN)
  • Table 64 Asia Pacific Hyperhidrosis Treatment Market Outlook, By Other End Users (2020-2028) ($MN)
  • Table 65 South America Hyperhidrosis Treatment Market Outlook, By Country (2020-2028) ($MN)
  • Table 66 South America Hyperhidrosis Treatment Market Outlook, By Treatment Type (2020-2028) ($MN)
  • Table 67 South America Hyperhidrosis Treatment Market Outlook, By Surgical Treatments (2020-2028) ($MN)
  • Table 68 South America Hyperhidrosis Treatment Market Outlook, By Topical Treatments (2020-2028) ($MN)
  • Table 69 South America Hyperhidrosis Treatment Market Outlook, By Botulin Toxin A (2020-2028) ($MN)
  • Table 70 South America Hyperhidrosis Treatment Market Outlook, By Laser Treatments (2020-2028) ($MN)
  • Table 71 South America Hyperhidrosis Treatment Market Outlook, By Iontophoresis (2020-2028) ($MN)
  • Table 72 South America Hyperhidrosis Treatment Market Outlook, By Other Treatment Types (2020-2028) ($MN)
  • Table 73 South America Hyperhidrosis Treatment Market Outlook, By Disease Type (2020-2028) ($MN)
  • Table 74 South America Hyperhidrosis Treatment Market Outlook, By Primary Focal Hyperhidrosis (2020-2028) ($MN)
  • Table 75 South America Hyperhidrosis Treatment Market Outlook, By Secondary Generalized Hyperhidrosis (2020-2028) ($MN)
  • Table 76 South America Hyperhidrosis Treatment Market Outlook, By End User (2020-2028) ($MN)
  • Table 77 South America Hyperhidrosis Treatment Market Outlook, By Hospitals (2020-2028) ($MN)
  • Table 78 South America Hyperhidrosis Treatment Market Outlook, By Homecare (2020-2028) ($MN)
  • Table 79 South America Hyperhidrosis Treatment Market Outlook, By Speciality Centres (2020-2028) ($MN)
  • Table 80 South America Hyperhidrosis Treatment Market Outlook, By Other End Users (2020-2028) ($MN)
  • Table 81 Middle East & Africa Hyperhidrosis Treatment Market Outlook, By Country (2020-2028) ($MN)
  • Table 82 Middle East & Africa Hyperhidrosis Treatment Market Outlook, By Treatment Type (2020-2028) ($MN)
  • Table 83 Middle East & Africa Hyperhidrosis Treatment Market Outlook, By Surgical Treatments (2020-2028) ($MN)
  • Table 84 Middle East & Africa Hyperhidrosis Treatment Market Outlook, By Topical Treatments (2020-2028) ($MN)
  • Table 85 Middle East & Africa Hyperhidrosis Treatment Market Outlook, By Botulin Toxin A (2020-2028) ($MN)
  • Table 86 Middle East & Africa Hyperhidrosis Treatment Market Outlook, By Laser Treatments (2020-2028) ($MN)
  • Table 87 Middle East & Africa Hyperhidrosis Treatment Market Outlook, By Iontophoresis (2020-2028) ($MN)
  • Table 88 Middle East & Africa Hyperhidrosis Treatment Market Outlook, By Other Treatment Types (2020-2028) ($MN)
  • Table 89 Middle East & Africa Hyperhidrosis Treatment Market Outlook, By Disease Type (2020-2028) ($MN)
  • Table 90 Middle East & Africa Hyperhidrosis Treatment Market Outlook, By Primary Focal Hyperhidrosis (2020-2028) ($MN)
  • Table 91 Middle East & Africa Hyperhidrosis Treatment Market Outlook, By Secondary Generalized Hyperhidrosis (2020-2028) ($MN)
  • Table 92 Middle East & Africa Hyperhidrosis Treatment Market Outlook, By End User (2020-2028) ($MN)
  • Table 93 Middle East & Africa Hyperhidrosis Treatment Market Outlook, By Hospitals (2020-2028) ($MN)
  • Table 94 Middle East & Africa Hyperhidrosis Treatment Market Outlook, By Homecare (2020-2028) ($MN)
  • Table 95 Middle East & Africa Hyperhidrosis Treatment Market Outlook, By Speciality Centres (2020-2028) ($MN)
  • Table 96 Middle East & Africa Hyperhidrosis Treatment Market Outlook, By Other End Users (2020-2028) ($MN)